Barclays Reaffirms Their Hold Rating on Blueprint Medicines (BPMC)
Barclays analyst Peter Lawson maintained a Hold rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of $105.00.
Barclays PLC Raises Stock Position in Regulus Therapeutics Inc. (NASDAQ:RGLS)
Barclays PLC lifted its holdings in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS – Free Report) by 285.2% during the 3rd quarter, Holdings Channel reports. The firm owned 84,477 shares of the ...
Barclays Remains a Hold on Five Below (FIVE)
In a report released today, Seth Sigman from Barclays maintained a Hold rating on Five Below (FIVE – Research Report), with a price target of ...